title: Thromboxane A2-induced arrhythmias in the anesthetized rabbit.
abstract: Experiments were conducted in the anesthetized rabbit to investigate mechanisms for arrhythmias that occur after left atrial injection of the thromboxane A(2) (TxA(2)) mimetic U-46619. Arrhythmias were primarily of ventricular origin, dose dependent in frequency, and TxA(2) receptor mediated. The response was receptor specific since arrhythmias were absent after pretreatment with a specific TxA(2) receptor antagonist (SQ-29548) and did not occur in response to another prostaglandin, PGF(2alpha). Alterations in coronary blood flow were unlikely the cause of these arrhythmias because coronary blood flow (as measured with fluorescent microspheres) was unchanged after U-46619, and there were no observable changes in the ECG-ST segment. In addition, arrhythmias did not occur after administration of another vasoconstrictor (phenylephrine). The potential involvement of autonomic cardiac efferent nerves in these arrhythmias was also investigated because TxA(2) has been shown to stimulate peripheral nerves. Pretreatment of animals with the beta-adrenergic receptor antagonist propranolol did not reduce the frequency of these arrhythmias. Pretreatment with atropine or bilateral vagotomy resulted in an increased frequency of arrhythmias, suggesting that parasympathetic nerves may actually inhibit the arrhythmogenic activity of TxA(2). These experiments demonstrate that left atrial injection of U-46619 elicits arrhythmias via a mechanism independent of a significant reduction in coronary blood flow or activation of the autonomic nervous system. It is possible that TxA(2) may have a direct effect on the electrical activity of the heart in vivo, which provides significant implications for cardiac events where TxA(2) is increased, e.g., after myocardial ischemia or administration of cyclooxygenase-2 inhibitors.
authors.affiliation: Dept. of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA. mjwacker@ku.edu
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wacker
authors.forename: Shaun R
authors.initials: SR
authors.lastname: Best
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Kosloski
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Stachura
authors.forename: Rory L
authors.initials: RL
authors.lastname: Smoot
authors.forename: Charles B
authors.initials: CB
authors.lastname: Porter
authors.forename: James A
authors.initials: JA
authors.lastname: Orr
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000008:administration & dosage*; D000758:Anesthesia; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000503:physiopathology*; D001783:Blood Flow Velocity / Q000187:drug effects*; D003326:Coronary Circulation / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D011817:Rabbits; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000378:metabolism*; D013928:Thromboxane A2 / Q000008:administration & dosage*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage
chemical_list: D044244:Receptors, Thromboxane A2, Prostaglandin H2; D014662:Vasoconstrictor Agents; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid